A cancer patient’s genetic ancestry can have a significant effect on how their disease progresses and on their survival. New research shows dozens of mutations that are significantly more or less common depending on the patient’s ancestry, about half of which can be targeted by existing treatments. A scoring system was able to predict patient survival, particularly so in breast cancer and glioma. When ancestry information was added, the survival prediction became even more accurate, particularly in cancer of the pancreas.

In people with type 2 diabetes, semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared to other anti-obesity medications, according to a study being presented Sunday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, Ill.

Steroids are widely prescribed but side effects are common. Researchers have found that certain genetic variants increase the risk of side effects such as osteoporosis, stroke, and cataracts and say that integrating these data into steroid prescribing can improve the prediction of risk and thus enable doctors to prescribe them more appropriately.

Adults with obesity losing weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which is essential to protect muscle, according to a study being presented Saturday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, Ill.

A study of a new AI model examining 30 years of routine electronic health records (EHR) data could improve screening for primary aldosteronism, a leading cause of high blood pressure that is often unrecognized but increases patients’ risk of cardiovascular complications, according to a study being presented Saturday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, Ill.

Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first-ever Phase 3 study of an in vivo CRISPR therapy. In this large-scale, double-blind Phase 3 trial, 80 patients with hereditary angioedema were randomized to receive either the CRISPR therapy or a placebo. CRISPR therapy is a medical technique that allows doctors to precisely modify errors in cellular DNA to treat specific hereditary diseases. Danny Cohn, leader of the research, is highly enthusiastic: "The study demonstrates that the therapy is genuinely effective and safe. This confirmation is exactly what regulatory authorities need to approve the very first in vivo CRISPR gene editing treatment for the market."